BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
During activation, T cells express receptors for receiving positive and negative costimulatory signals. Here we identify the B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BTLA inhibits T/B cell activation and the secretion of cytokines11”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“anti-BTLA crosslinking may also cause the phosphorylation of the Src-homology domain 2 (SH2)-containing proteins tyrosine phosphatase-1 (SHP-1) and SHP-2 to activate suppression signaling”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“Additionally, the western blotting demonstrated that crosslinked BTLA promotes the phosphorylation of SHP-1/2, consistent with findings from previous studies11,42, and also activates the PI3K-Akt-GSK-3β pathway in purified CD4+ T cells.”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“BTLA is the essential co‐signaling immune checkpoint protein with bidirectional functions [331].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [331]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“, and Y282 is similar to the immunoreceptor tyrosine-based switch motif (ITSM) in PD-1 (ref”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 2
- Chambers, C.A. et al. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol. 28, 3137–3143 (1998). · doi:10.1002/(sici)1521-4141(199810)28:10<3137::aid-immu3137>3.0.co;2-x
- Bachmann, M.F. et al. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur. J. Immunol. 31, 450–458 (2001). · DOI · Paper page
Cited by
Items 201–300 of 894
Sagar, Pokrovskii, M. V., Herman, J. S., Naik, S., Sock, E., Zeis, P., Lausch, U., Wegner, M., Tanriver, Y., Littman, D. R., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019104159 · Cited by 83
“Adult Sox13 -deficient immature cd T cells expressed higher levels of Cd28 and Btla , a receptor for the B7 homolog B7x (Fig 5H) (Watanabe et al , 2003).”
Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target
MacGregor, H. L., & Ohashi, P. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2440 · Cited by 81
The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM–BTLA
Croft, M. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.03.010 · Cited by 77
“Sedy et al. demonstrate that HVEM binding to BTLA promotes the association of SHP-2 with BTLA [ 1 ], and together with Gonzalez [2], show BTLA then suppresses T-cell division.”
BackgroundInfluentialPasero, C., Speiser, D. E., Derré, L., & Olive, D. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.03.001 · Cited by 80
Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention
Norde, W. J., Hobo, W. A., van der Voort, R., & Dolstra, H. (2012) · Blood · doi:10.1182/blood-2012-02-412510 · Cited by 91
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 79
The DC‐HIL/syndecan‐4 pathway inhibits human allogeneic T‐cell responses
Chung, J., Bonkobara, M., Tomihari, M., Cruz, P. D., & Ariizumi, K. (2009) · European Journal of Immunology · doi:10.1002/eji.200838990 · Cited by 73
“Because TCR signaling can be deleted by dephosphorylating molecules, and because CTLA-4, PD-1, and BTLA associate with protein tyrosine phosphatase (PTP) to mediate inhibitory function [5,30,31], we postulate that SD-4 signaling involves some linkage with a PTP.”
BackgroundKaufman, H. L., Taback, B., Sherman, W. H., Kim, D. W., Shingler, W. H., Moroziewicz, D. N., DeRaffele, G., Mitcham, J., Carroll, M. W., Harrop, R., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-2 · Cited by 77
“co-inhibitory receptor, was significantly elevated in both CD4+ and CD8+ T cells in patients with progressive disease [25-27].”
Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations
Soroosh, P., Doherty, T. A., So, T., Mehta, A. K., Khorram, N., Norris, P. S., Scheu, S., Pfeffer, K., Ware, C. F., & Croft, M. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20101562 · Cited by 76
“…for the latter phenotypes is that HVEM can also bind to BTLA and CD160, and these mole cules can induce inhibitory signals into T cells when ex pressed in cis or in trans in T cells (Watanabe et al., 2003; JEM VOL. 208, April 11, 2011 Article 807 was used to visualize biotinlabeled antibodies.”
BackgroundMethodImmune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy
Kodumudi, K. N., Siegel, J., Weber, A. M., Scott, E., Sarnaik, A. A., & Pilon-Thomas, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153053 · Cited by 74
“BTLA belongs to CD28 family and is structurally similar to CTLA-4 and PD-1 [10].”
BackgroundWu, Y., Gu, W., Li, J., Chen, C., & Xu, Z. P. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0237 · Cited by 76
Co-signal Molecules in T-Cell Activation: Historical Overview and Perspective
Azuma, M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_1 · Cited by 84
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective
Nallasamy, P., Chava, S. P., Verma, S. S., Mishra, S., Gorantla, S., Coulter, D. W., Byrareddy, S. N., Batra, S. K., Gupta, S. C., & Challagundla, K. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.009 · Cited by 84
Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
Buckle, I., & Guillerey, C. (2021) · Cancers · doi:10.3390/cancers13174263 · Cited by 79
“B and T cell lymphocyte attenuator (BTLA/CD272) is a CD28/B7 superfamily member structurally and functionally similar to CTLA-4 and PD-1 [111].”
BackgroundImmune Checkpoint Receptors Signaling in T Cells
Baldanzi, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073529 · Cited by 80
“Akin to PD-1, the tail of BTLA contains two additional tyrosines (Y226 and Y243) involved in Grb2 binding, an ITIM (IVY257ASL), and an ITSM (TEY282ASI)) [63,64].”
BackgroundPutting the brakes on BTLA in T cell–mediated cancer immunotherapy
Paulos, C. M., & June, C. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41811 · Cited by 77
T lymphocyte co-signaling pathways of the B7-CD28 family.
Wang, S., & Chen, L. (2004) · PubMed · Cited by 74
CD28 and ICOS: Similar or separate costimulators of T cells?
van Berkel, M. E. A. T., & Oosterwegel, M. A. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.02.007 · Cited by 84
Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Ritthipichai, K., Haymaker, C., Martinez, M., Aschenbrenner, A., Yi, X., Zhang, M., Kale, C., Vence, L. M., Roszik, J., Hailemichael, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1217 · Cited by 80
Induction of tumor NK-cell immunity by anti-CD69 antibody therapy
Esplugues, E., Vega‐Ramos, J., Cartoixà, D., Vázquez, B. N., Salaet, I., Engel, P., & Lauzurica, P. (2005) · Blood · doi:10.1182/blood-2004-10-3854 · Cited by 88
Kashiwakuma, D., Suto, A., Hiramatsu, Y., Ikeda, K., Takatori, H., Suzuki, K., Kagami, S.-I., Hirose, K., Watanabe, N., Iwamoto, I., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903839 · Cited by 70
“Because BTLA is expressed on B cells (20, 29) and was reported to function as an inhibitory coreceptor on BCR signaling (30), we next performed another adoptive-transfer experiment in which BTLA mice were used as recipients to address the role of BTLA expressed on B cells in the development of GC B cells and IgG produ…”
BackgroundMethodResultSelf-citationThe immunoregulatory effects of Qa‐1
Lu, L., Werneck, M. B. F., & Cantor, H. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00418.x · Cited by 72
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 78
Serriari, N.-E., Gondois-Rey, F., Guillaume, Y., Remmerswaal, E. B. M., Pastor, S., Messal, N., Truneh, A., Hirsch, I., van Lier, R. A. W., & Olive, D. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902487 · Cited by 70
“First, BTLA was initially identified as having inhibitory actions on T cell proliferation and cytokine production in vitro (11, 12).”
BackgroundInfluentialHVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT
Rodríguez-Barbosa, J.-I., Schneider, P., Weigert, A., Lee, K., Kim, T.-J., Pérez‐Simón, J. A., & del Rio, M. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0241-1 · Cited by 73
Detection of Immune Checkpoint Receptors – A Current Challenge in Clinical Flow Cytometry
Shibru, B., Fey, K., Fricke, S., Blaudszun, A., Fürst, F., Weise, M., Seiffert, S., Weyh, M. K., Koehl, U., Sack, U., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694055 · Cited by 84
Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity
Pasero, C., & Olive, D. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.01.008 · Cited by 78
Hobo, W., Norde, W. J., Schaap, N., Fredrix, H., Maas, F., Schellens, K., Falkenburg, J. H. F., Korman, A. J., Olive, D., van der Voort, R., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102807 · Cited by 68
CD6, a Rheostat-Type Signalosome That Tunes T Cell Activation
Gonçalves, C. M., Henriques, S. N., Santos, R. F., & Carmo, A. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02994 · Cited by 75
BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
Demerle, C., Gorvel, L., & Olive, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682007 · Cited by 72
CEACAM1 Dynamics during Neisseria gonorrhoeae Suppression of CD4+ T Lymphocyte Activation
Lee, H. S. W., Ostrowski, M., & Gray‐Owen, S. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.6827 · Cited by 69
Albring, J. C., Sandau, M. M., Rapaport, A. S., Edelson, B. T., Satpathy, A., Mashayekhi, M., Lathrop, S. K., Hsieh, C.-S., Stelljes, M., Colonna, M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20102017 · Cited by 68
“RESULTS AND DISCUSSION To determine the role of BTLA in the development of GVHD, we first examined WT and BTLA/ donor mice (Watanabe et al., 2003) using a nonlethal parentintoirradiated F1 model of aHSCT (Stelljes et al.”
BackgroundMethodInfluentialSelf-citationImmune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk
Wagner, M., Jasek, M., & Karabon, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606721 · Cited by 80
Noncoding RNAs: the shot callers in tumor immune escape
Liu, L., Wang, Q., Qiu, Z., Kang, Y., Liu, J., Ning, S., Yin, Y., Pang, D., & Xu, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0194-y · Cited by 70
“Moreover, BTLA-deficient T cells show increased proliferation.(185) As mentioned in the previous section, in melanoma, miR-28 can inhibit the expression of BTLA, PD-1, and CTLA-4 in T cells, which could enhance the antitumor immune response and inhibit TIE.”
BackgroundInfluentialCardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
Pirozzi, F., Poto, R., Aran, L., Cuomo, A., Galdiero, M. R., Spadaro, G., Abete, P., Bonaduce, D., Marone, G., Tocchetti, C. G., et al. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01002-w · Cited by 71
Shankar, E. M., Che, K. F., Messmer, D., Lifson, J. D., & Larsson, M. (2010) · Molecular Medicine · doi:10.2119/molmed.2010.00175 · Cited by 69
Stiles, K. M., Whitbeck, J. C., Lou, H., Cohen, G. H., Eisenberg, R. J., & Krummenacher, C. (2010) · Journal of Virology · doi:10.1128/jvi.01550-10 · Cited by 68
“BTLA is expressed on mature lymphocytes, macrophages, and dendritic cells (75) and is thought to be a dimer on the cell surface (10).”
BackgroundHaymaker, C., Wu, R. C. H., Ritthipichai, K., Bernatchez, C., Forget, M., Chen, J. Q., Liu, H., Wang, E., Marincola, F. M., Hwu, P., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1014246 · Cited by 69
“This could potentially occur through the conserved YXN motif upstream of the ITIM and ITSM motifs in BTLA.(5) In the platelet-derived growth factor (PDGF) receptor, this YXN motif has been found to bind to the signaling adaptor protein Grb-2 following phosphorylation of the tyrosine, leading to recruitment of phosphat…”
BackgroundInfluentialThe perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation
Blank, C. U. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000054 · Cited by 68
“The T-cell inhibitory function of BTLA (B and T lymphocyte attenuator) was proven in the Btla-knockout mice, and its ligand, herpes entry mediator (HVEM, TNFRSF14) is expressed on tumor cells and tumorassociated endothelia [94,95].”
BackgroundDing, H., Wu, X., Wu, J., Yagita∥, H., He, Y., Zhang, J., Ren, J., & Gao, W. (2006) · Clinical Immunology · doi:10.1016/j.clim.2005.10.017 · Cited by 68
SHP2 forecast for the immune system: fog gradually clearing
Salmond, R. J., & Alexander, D. R. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.01.007 · Cited by 74
The Role of Coinhibitory Signaling Pathways in Transplantation and Tolerance
McGrath, M. M., & Najafian, N. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00047 · Cited by 67
“It is most commonly seen in chronic viral infections and malignancies and is thought to relate to chronic antigenic stimulation (Wherry et al., 2003).”
BackgroundDong, M. P., Enomoto, M., Thủy, L. T. T., Hai, H., Hieu, V. N., Hoang, D. V., Iida‐Ueno, A., Odagiri, N., Amano‐Teranishi, Y., Hagihara, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60440-5 · Cited by 69
Mirzaei, H. R., Pourghadamyari, H., Rahmati, M., Mohammadi, A., Nahand, J. S., Rezaei, A., Mirzaei, H., & Hadjati, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.03.010 · Cited by 65
Khosravi, N., Mokhtarzadeh, A., Baghbanzadeh, A., Hajiasgharzadeh, K., Khaze, V., Hemmat, N., Safarzadeh, E., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118005 · Cited by 66
Oguro, S., Ino, Y., Shimada, K., Hatanaka, Y., Matsuno, Y., Esaki, M., Nara, S., Kishi, Y., Kosuge, T., & Hiraoka, N. (2015) · Cancer Science · doi:10.1111/cas.12825 · Cited by 68
Targeting B7‐1 in immunotherapy
Chen, R., Ganesan, A., Okoye, I., Arutyunova, E. I., Elahi, S., Lemieux, M. J., & Barakat, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21632 · Cited by 67
The role of ICOS and other costimulatory molecules in allergy and asthma
Coyle, A. J., & Gutierrez-Ramos, J.-C. (2004) · Springer Seminars in Immunopathology · doi:10.1007/s00281-003-0154-y · Cited by 62
“BTLA [58] B7x [61] B7S B7H-3 [13] B7RP-2”
BackgroundNeoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
Touhami, S., Audo, I. S., Terrada, C., Gaudric, A., LeHoang, P., Touitou, V., & Bodaghi, B. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.05.002 · Cited by 63
Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
Xu, X., Masubuchi, T., Cai, Q., Zhao, Y., & Hui, E. (2021) · eLife · doi:10.7554/elife.74276 · Cited by 59
Liu, X., Alexiou, M., Martin-Orozco, N., Chung, Y., Nurieva, R. I., Ma, L., Tian, Q., Kollias, G., Lu, S., Graf, D., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803161 · Cited by 59
“In keeping with previous findings (5, 7), BTLA-deficient T cells showed a heightened response to anti-CD3 stimulation.”
BackgroundResultKobayashi, Y., Iwata, A., Suzuki, K., Suto, A., Kawashima, S., Saito, Y., Owada, T., Kobayashi, M., Watanabe, N., & Nakajima, H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222093110 · Cited by 59
“B and T lymphocyte attenuator (BTLA; CD272) is the third inhibitory coreceptor, which has been identified as an inhibitory coreceptor expressed on CD4 T cells and B cells with similarities to CTLA-4 and PD-1 (9).”
BackgroundMethodSelf-citationEnhanced CD4 T Cell Responsiveness in the Absence of 4-1BB
Lee, S., Vella, A. T., Kwon, B. S., & Croft, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6803 · Cited by 63
“However, recent data with HVEM-deficient cells have also demonstrated hyperresponsiveness (K. Potter and C. Ware, unpublished observations), somewhat similar to the phenotype we describe in this study with 4-1BB. HVEM has now been shown to also bind the ITIMcontaining molecule B and T lymphocyte attenuator (BTLA) that…”
BackgroundEmerging Targets in Cancer Immunotherapy: Beyond CTLA-4 and PD-1
Assal, A., Kaner, J. D., Pendurti, G., & Zang, X. (2015) · Immunotherapy · doi:10.2217/imt.15.78 · Cited by 59
Self-citationCheck Point Inhibitors and Their Role in Immunosuppression in Sepsis
Wakeley, M. E., Gray, C. C., Monaghan, S. F., Heffernan, D. S., & Ayala, A. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2019.08.006 · Cited by 63
SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
Niogret, C., Birchmeier, W., & Guarda, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02468 · Cited by 58
“In addition to SHP-2, SHP-1 has been shown to interact with PD-1 and other IRs, albeit to a lesser extent (136, 137, 143, 144).”
BackgroundPhenotypic and genetic analyses of T‐cell‐mediated immunoregulation in patients with Type 1 diabetes
Tsutsumi, Y., Jie, X., Ihara, K., Nomura, A., Kanemitsu, S., Takada, H., & Hara, T. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01951.x · Cited by 63
CD8 T Cell Memory to a Viral Pathogen Requires Trans Cosignaling between HVEM and BTLA
Flynn, R., Hutchinson, T., Murphy, K. M., Ware, C. F., Croft, M., & Salek-Ardakani, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077991 · Cited by 57
“Consistent with a proposed role as an inhibitory co-signaling receptor, BTLA-deficient T cells show increased proliferation [25,27,28], and BTLA-knockout mice have enhanced susceptibility to autoimmune disease and increased inflammatory responses [15,25,27,29,30,31,32,33,34].”
BackgroundSelf-citationPatsoukis, N., Weaver, J. D., Strauss, L., Herbel, C., Seth, P., & Boussiotis, V. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00330 · Cited by 60
“BTLA contains two conserved ITIMs in its cytoplasmic tail (129), which are phosphorylated on Y274 and Y299 upon BTLA ligation and result in recruitment of SHP-1 and SHP-2 (18, 174, 175, 185).”
BackgroundInfluentialImmune sensitization during 1 year in the Antarctic high‐altitude Concordia Environment
Feuerecker, M., Crucian, B. E., Quintens, R., Buchheim, J., Salam, A. P., Rybka, A., Moreels, M., Strewe, C., Stowe, R., Mehta, S. K., et al. (2018) · Allergy · doi:10.1111/all.13545 · Cited by 65
Li, X., Xu, Z., Cui, G., Li, Y., & Zhang, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232234 · Cited by 63
Steinberg, M. W., Huang, Y., Wang-Zhu, Y., Ware, C. F., Cheroutre, H., & Kronenberg, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077992 · Cited by 55
“Btla [3] and Hvem [9] mice were generously provided by Dr.”
BackgroundInfluentialRigid-body Ligand Recognition Drives Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Receptor Triggering
Yu, C., Sonnen, A. F. ‐., George, R., Dessailly, B. H., Stagg, L., Evans, E. J., Orengo, C. A., Stuart, D. I., Ladbury, J. E., Ikemizu, S., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.182394 · Cited by 56
Reflections on CD8 T-Cell Activation and Memory
Masopust, D., & Ahmed, R. (2004) · Immunologic Research · doi:10.1385/ir:29:1-3:151 · Cited by 62
Costimulation Blockade in the Treatment of Rheumatic Diseases
Liossis, S. C., & Sfikakis, P. P. (2004) · BioDrugs · doi:10.2165/00063030-200418020-00003 · Cited by 55
Immune barriers to successful gene therapy
Wu, T.-L., & Ertl, H. C. J. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.005 · Cited by 57
Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway
Sakoda, Y., Park, J.-J., Zhao, Y., Kuramasu, A., Geng, D., Liu, Y., Davila, E., & Tamada, K. (2011) · Blood · doi:10.1182/blood-2010-08-301325 · Cited by 54
Immune checkpoint inhibitors: a patent review (2010-2015)
Collin, M. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1176150 · Cited by 58
“B- and T-lymphocyte attenuator (BTLA) was identified as another negative checkpoint regulator in the IgSF structurally related to CTLA-4 and PD-1.”
BackgroundInfluentialAnderson, P. O., & González‐Rey, E. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01282-09 · Cited by 57
Piancone, F., Saresella, M., Marventano, I., La Rosa, F., Zoppis, M., Agostini, S., Longhi, R., Caputo, D., Mendozzi, L., Rovaris, M., et al. (2016) · Scientific Reports · doi:10.1038/srep29699 · Cited by 48
Choi, J. H., Medikonda, R. T., Saleh, L., Kim, T., Pant, A., Srivastava, S., Kim, Y., Jackson, C., Tong, L., Routkevitch, D., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1956142 · Cited by 55
“B and T lymphocyte attenuator (BTLA) is a co-inhibitory checkpoint molecule that is structurally related to PD-1.(13) Previous studies have shown that BTLA is highly expressed on tumor-specific T cells in cancer patients(14) and is upregulated in several cancers including gastric cancer,(15) hepatocellular carcinoma,(…”
BackgroundTruong, W., Plester, J. C., Hancock, W. W., Merani, S., Murphy, T. L., MURPHY, K. M. M., Kaye, J., Anderson, C. C., & Shapiro, A. M. J. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01996.x · Cited by 54
“Although BTLA-deficient mice have normal B and T cell development, these mice have exacerbated responses in the experimental autoimmune encephalomyelitis model (16) and worse disease in a model of allergic airway inflammation (21).”
BackgroundSelf-citationMaster switches of T-cell activation and differentiation
Beier, K. C., Kallinich, T., & Hamelmann, E. H. (2007) · European Respiratory Journal · doi:10.1183/09031936.00094506 · Cited by 64
“It is upregulated on T-cells upon activation [ 40 ].”
BackgroundMcGee, H. S., & Agrawal, D. K. (2006) · Immunologic Research · doi:10.1385/ir:35:3:219 · Cited by 64
“Expression of BTLA is subsequently lost on highly polarized TH2 cells, but is maintained on TH1 cells ( 54 ).”
BackgroundInfluentialProteomic Profiling of Surface Proteins on Th1 and Th2 Cells
Loyet, K. M., Ouyang, W., Eaton, D., & Stults, J. T. (2005) · Journal of Proteome Research · doi:10.1021/pr049810q · Cited by 55
BTLA biology in cancer: from bench discoveries to clinical potentials
Andrzejczak, A., & Karabon, L. (2024) · Biomarker Research · doi:10.1186/s40364-024-00556-2 · Cited by 56
“BTLA structure BTLA (also known as CD272) was discovered 20 years ago initially as a transcript, highly specific to Th1 cells [9].”
BackgroundThe BTLA–HVEM axis restricts CAR T cell efficacy in cancer
Guruprasad, P., Carturan, A., Zhang, Y., Cho, J. H., Kumashie, K. G., Patel, R. P., Kim, K.-H., Lee, J.-S., Lee, Y., Kim, J. H., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01847-4 · Cited by 55
Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer
Liu, X., Xi, X., Xu, S., Chu, H., Hu, P., Li, D., Zhang, B., Liu, H., Jiang, T., & Lu, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1507501 · Cited by 57
B and T Lymphocyte Attenuator Tempers Early Infection Immunity
Sun, Y., Brown, N. K., Ruddy, M. J., Miller, M. L., Lee, Y., Wang, Y., Murphy, K. M., Pfeffer, K., Chen, L., Kaye, J., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801866 · Cited by 51
“tal autoimmune encephalomyelitis (11, 15), enhanced rejection of”
BackgroundSelf-citationDistinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells
Wang, X. ‐., Chen, Y. ‐., Wang, Q., Ge, Y., Dai, Q., Yang, K. ‐., Fang‐Xie, Zhou, Y. ‐., Hu, Y. ‐., Mao, Y. ‐., et al. (2007) · Tissue Antigens · doi:10.1111/j.1399-0039.2006.00710.x · Cited by 51
Current concepts of non-coding RNA regulation of immune checkpoints in cancer
Smolle, M. A., Prinz, F., Calin, G. A., & Pichler, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.09.007 · Cited by 52
Co‐stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily
Peggs, K. S., & Allison, J. P. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05627.x · Cited by 60
Self-citationPD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation
del Rio, M., Bühler, L. H., Gibbons, C., Tian, J., & Rodríguez-Barbosa, J.-I. (2008) · Transplant International · doi:10.1111/j.1432-2277.2008.00726.x · Cited by 57
“The BTLA gene was initially isolated from a cDNA clone expressed mainly in Th1 cells [69].”
BackgroundHan, L., Wang, W., Fang, Y., Feng, Z., Liao, S., Li, W., Li, Y., Li, C., Maitituoheti, M., Dong, H., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804379 · Cited by 52
“sive to TCR-mediated T cell activation (1).”
BackgroundLasaro, M. O., Sazanovich, M., Giles-Davis, W., Mrass, P., Bunte, R. M., Sewell, D. A., Hussain, S. F., Fu, Y.-X., Weninger, W., Paterson, Y., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.88 · Cited by 48
BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma
Zhao, Q., Huang, Z.-L., He, M., Gao, Z., & Kuang, D.-M. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1254855 · Cited by 46
“The elevated expression of programmed cell death 1 (PD-1) on tumor-infiltrating T cells has become an accepted signature for a state called T cell “exhaustion” in cancer.1-4 The blockade of PD-1 can reverse T cell exhaustion and restore antigen-specific T cell responses, highlighting the therapeutic significance of PD…”
BackgroundResultInfluentialThe Role of the CD28 Family Receptors in T-Cell Immunomodulation
Ciesielska-Figlon, K., & Lisowska, K. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021274 · Cited by 50
New Insights into the Role of PD-1 and Its Ligands in Allergic Disease
Galván Morales, M. A., Montero-Vargas, J. M., Vizuet-de-Rueda, J. C., & Teran, L. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111898 · Cited by 45
“BTLA-deficient T cells show increased proliferation, the same as in PD-1−/− mice [56,57].”
BackgroundPDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders
James, E. S., Harney, S. M. J., Wordsworth, B. P., Cookson, W., Davis, S. J., & Moffatt, M. F. (2005) · Genes and Immunity · doi:10.1038/sj.gene.6364223 · Cited by 49
Fu, Z., Li, D., Jiang, W., Wang, L., Zhang, J., Xu, F., Pang, D., & Li, D. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0462-6 · Cited by 48
“The inhibitory signal of BTLA appears to be mediated by the recruitment of SHP-1 and SHP-2 to two immunoreceptor tyrosine inhibitory motifs (ITIMs) in the cytoplasmic region of BTLA [3, 4].”
BackgroundMiller, M. L., Sun, Y., & Fu, Y.-X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900690 · Cited by 46
“We and others have shown that the absence of BTLA-HVEM inhibitory interactions leads to increased experimental autoimmune encephalomyelitis severity (9, 11), enhanced rejection of partially mismatched allografts (12), an increased CD8 memory T cell population (13), increased severity of colitis (14), reduced effective…”
BackgroundLigation of B and T Lymphocyte Attenuator Prevents the Genesis of Experimental Cerebral Malaria
Lepenies, B., Pfeffer, K., Hurchla, M. A., Murphy, T. L., Murphy, K. M., Oetzel, J., Fleischer, B., & Jacobs, T. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.4093 · Cited by 46
“B and T lymphocyte attenuator (BTLA) is a recently discovered inhibitory receptor on T cells that shares structural and functional similarities with CTLA-4 and PD-1 (15).”
Self-citationYu, X., Yang, F., Shen, Z., Zhang, Y., Sun, J., Qiu, C., Zheng, Y., Zhao, W., Yuan, S., Zeng, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46047-8 · Cited by 47
“Additionally, the western blotting demonstrated that crosslinked BTLA promotes the phosphorylation of SHP-1/2, consistent with fi ndings from previous studies 11,42 , and also activates the PI3K-Akt-GSK-3 β pathway in puri fi ed CD4 + T cells.”
BackgroundMethodSafavi, S., Hansson, M., Karlsson, K., Biloglav, A., Johansson, B., & Paulsson, K. M. (2014) · Haematologica · doi:10.3324/haematol.2014.112912 · Cited by 47
Armed Therapeutic Viruses – A Disruptive Therapy on the Horizon of Cancer Immunotherapy
Bauzon, M., & Hermiston, T. W. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00074 · Cited by 53
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia
Knaus, H. A., Kanakry, C. G., Luznik, L., & Gojo, I. (2017) · Current Drug Targets · doi:10.2174/1389450116666150518095346 · Cited by 51
BTLA and HVEM Cross Talk Regulates Inhibition and Costimulation
Gavrieli, M., Šedý, J. R., Nelson, C. A., & MURPHY, K. M. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)92004-5 · Cited by 50
Self-citationDiniz, M. O., Lasaro, M. O., Ertl, H. C. J., & Ferreira, L. C. D. S. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00264-10 · Cited by 47
“BTLA provides inhibitory signals to T and B cells upon binding to HVEM (7, 38).”
BackgroundInfluentialThe New Era of Cancer Immunotherapy
Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., Henau, O. D., Zamarin, D., Holmgaard, R., Murphy, J. T., et al. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.010 · Cited by 51
Quan, L., Lan, X., Meng, Y., Guo, X., Guo, Y., Zhao, L., Chen, X., & Liu, A. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.01.003 · Cited by 47
Metadata
- Authors
- Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., Murphy, T. L., Russell, J. H., Allison, J. P., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Boehringer Ingelheim (Germany) (DE)
- University of Perugia (IT)
- Washington University in St. Louis (US)
- Corresponding author
- Murphy, Kenneth M
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-06-08
- Volume
- 4
- Issue
- 7
- Pages
- 670-679
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2118705059
- Cited by
- 883
- References
- 52
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 38 · 2023: 38 · 2022: 38 · 2021: 59 · 2020: 56 · 2019: 49 · 2018: 35 · 2017: 29 · 2016: 31 · 2015: 36 · 2014: 34 · 2013: 41 · 2012: 37
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- BTLA, inhibitory receptors, T cell costimulation, CTLA-4, PD-1, SHP-1, SHP2, tyrosine phosphorylation, interleukin-2, T helper cell differentiation, B7 ligands, T cell proliferation, experimental autoimmune encephalomyelitis, antibody response
- MeSH terms
- Abatacept, Amino Acid Sequence, Animals, Antigens, Differentiation, Antigens, Surface, Encephalomyelitis, Autoimmune, Experimental, Interleukin-2, Lymphocyte Activation, Molecular Sequence Data, Phosphorylation, Proteins, Receptors, Immunologic, RNA, Messenger, T-Lymphocytes, Antigens, CD, Protein Tyrosine Phosphatases, B7-1 Antigen, Immunoconjugates, Intracellular Signaling Peptides and Proteins, Apoptosis Regulatory Proteins, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatase, Non-Receptor Type 11, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.